172 related articles for article (PubMed ID: 28184434)
21. Allele and Genotype Frequencies of Cytochrome P450 2B6 516G>T Single Nucleotide Polymorphism in HIV-Negative and HIV-Infected Adult Nigerian Populations.
Saʼad Toyin A; Julius Olugbenga S; Rahman Ayodele B; Olusola Joseph O; Taibat Moji BO
Am J Ther; 2016; 23(6):e1715-e1719. PubMed ID: 26938766
[TBL] [Abstract][Full Text] [Related]
22. Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction.
Chiang YC; Wang RY; Huang CL; Chen SH; Ho WJ; Lane HY; Ho IK; Yang HT; Ma WL
J Cell Mol Med; 2017 Dec; 21(12):3552-3564. PubMed ID: 28699698
[TBL] [Abstract][Full Text] [Related]
23. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
24. ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients.
Sutlović D; Ključević Ž; Kuret S
Arh Hig Rada Toksikol; 2020 Dec; 71(4):353-358. PubMed ID: 33410778
[TBL] [Abstract][Full Text] [Related]
25. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
26. CYP2B6 and OPRM1 Receptor Polymorphisms at Methadone Clinics And Novel OPRM1 Haplotypes: A Cross-Sectional Study.
AlMeman AA; Ismail R; Perola M
Drug Metab Lett; 2016; 10(3):213-218. PubMed ID: 27515451
[TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles.
Restrepo JG; Martínez C; García-Agúndez A; Gaviria E; Laguna JJ; García-Martín E; Agúndez JA
Pharmacogenet Genomics; 2011 Dec; 21(12):773-8. PubMed ID: 21886015
[TBL] [Abstract][Full Text] [Related]
28. A brief review of the genetics and pharmacogenetics of opioid use disorders.
Berrettini W
Dialogues Clin Neurosci; 2017 Sep; 19(3):229-236. PubMed ID: 29302220
[TBL] [Abstract][Full Text] [Related]
29. Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications.
Chalabianloo F; Fadnes LT; Johansson KA; Høiseth G; Vold JH; Kringen MK; Spigset O; Bramness JG
Basic Clin Pharmacol Toxicol; 2024 Mar; 134(3):333-344. PubMed ID: 38124280
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
[TBL] [Abstract][Full Text] [Related]
31. Current Concepts in Methadone Metabolism and Transport.
Kharasch ED
Clin Pharmacol Drug Dev; 2017 Mar; 6(2):125-134. PubMed ID: 28263461
[TBL] [Abstract][Full Text] [Related]
32. Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.
Yang HC; Chu SK; Huang CL; Kuo HW; Wang SC; Liu SW; Ho IK; Liu YL
PLoS Genet; 2016 Mar; 12(3):e1005910. PubMed ID: 27010727
[TBL] [Abstract][Full Text] [Related]
33. Comparison of fatal poisonings by prescription opioids.
Häkkinen M; Launiainen T; Vuori E; Ojanperä I
Forensic Sci Int; 2012 Oct; 222(1-3):327-31. PubMed ID: 22884575
[TBL] [Abstract][Full Text] [Related]
34. Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response.
Dinis-Oliveira RJ
Drug Metab Rev; 2016 Nov; 48(4):568-576. PubMed ID: 27320437
[TBL] [Abstract][Full Text] [Related]
35. Assessment of CYP450 genetic variability effect on methadone dose and tolerance.
Tsai HJ; Wang SC; Liu SW; Ho IK; Chang YS; Tsai YT; Lin KM; Liu YL
Pharmacogenomics; 2014 May; 15(7):977-86. PubMed ID: 24956251
[TBL] [Abstract][Full Text] [Related]
36. Distinctiveness of the Roma population within CYP2B6 worldwide variation.
Tomas Ž; Kuhanec A; Škarić-Jurić T; Petranović MZ; Narančić NS; Janićijević B; Salihović MP
Pharmacogenomics; 2017 Nov; 18(17):1575-1587. PubMed ID: 29095103
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population.
Zhang J; Ma S; Zhou W; Feng J; Kang Y; Yang W; Zhang H; Deng F
Toxicol Appl Pharmacol; 2023 Dec; 481():116770. PubMed ID: 37995809
[TBL] [Abstract][Full Text] [Related]
38. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
Haroun F; Al-Shaar L; Habib RH; El-Saghir N; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; Cascorbi I; Zgheib NK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):207-14. PubMed ID: 25428516
[TBL] [Abstract][Full Text] [Related]
39. CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide.
Labib RM; A Abdelrahim ME; Elnadi E; Hesham RM; Yassin D
PLoS One; 2016; 11(7):e0158890. PubMed ID: 27388155
[TBL] [Abstract][Full Text] [Related]
40. Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations.
Kim JH; Cheong HS; Park BL; Kim LH; Shin HJ; Na HS; Chung MW; Shin HD
Arch Pharm Res; 2015 Jan; 38(1):115-28. PubMed ID: 24988984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
